



PATENT  
ATTORNEY DOCKET NO. 00786/351004

Certificate of Mailing: Date of Deposit: March 2, 1999

I hereby certify under 37 CFR 1.8(a) that this correspondence is being deposited with the United States Postal Service as **first class mail** with sufficient postage on the date indicated above and is addressed to: Assistant Commissioner of Patents, Washington, D.C. 20231.

Lisa Fothergill  
Printed name of person mailing correspondence

Lisa Fothergill  
Signature of person mailing correspondence

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Gary Ruvkun et al.

Art Unit:

Serial No.: 09/205,658

Examiner:

Filed: December 3, 1998

Title: THERAPEUTIC AND DIAGNOSTIC TOOLS FOR IMPAIRED  
GLUCOSE TOLERANCE CONDITIONS

Assistant Commissioner of Patents  
Washington, D.C. 20231

PETITION TO CORRECT FILING RECEIPT

Applicant requests that the attached filing receipt be corrected as follows:

In the title, "Therapuetic" should be --Therapeutic--.


Attached is a copy of the incorrect filing receipt, transmittal, cover sheet, and first page of the application.


If there are any charges, or any credits, please apply them to Deposit Account No.

03-2095.

Respectfully submitted,

Date: March 2, 1999

  
\_\_\_\_\_  
Karen L. Elbing, Ph.D.  
Reg. No. 35,238

  
# 36,162

Clark & Elbing LLP  
176 Federal Street  
Boston, MA 02110  
Telephone: 617-428-0200  
Facsimile: 617-428-7045


FILING RECEIPT



UNITED STATES DEPARTMENT OF COMMERCE  
Patent and Trademark Office  
ASSISTANT SECRETARY AND COMMISSIONER  
OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTORNEY DOCKET NO.	DRWGS	TOT CL	IND CL
09/205,658	12/03/98	1633	\$1,636.00	00786/351004	69	34	11

KAREN L ELBING  
CLARK & ELBING  
176 FEDERAL STREET  
BOSTON MA 02110



DOCKETED FOR  
ATTORNEY ATTENTION

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Application Processing Division's Customer Correction Branch within 10 days of receipt. Please provide a copy of the Filing Receipt with the changes noted thereon.

Applicant(s)

GARY RUVKUN, NEWTON, MA; SCOTT OGG, NEWTON, MA.

TITLE

THERAPUETIC AND DIAGNOSTIC TOOLS FOR IMPAIRED GLUCOSE TOLERANCE  
CONDITIONS

PRELIMINARY CLASS: 424

DATA ENTRY BY: ARMSTEAD, LORRAINE TEAM: 06 DATE: 01/04/99

(see reverse)

Certificate of Mailing

Date of Deposit December 3, 1998

Label Number: EE632489272US

I hereby certify under 37 CFR 1.10 that this correspondence is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee" with sufficient postage on the date indicated above and is addressed to BOX PATENT APPLICATION, Assistant Commissioner of Patents, Washington, D.C. 20231.

Sandra E. Marxen  
Printed name of person mailing correspondence

  
Signature of person mailing correspondence



APPLICATION  
FOR  
UNITED STATES LETTERS PATENT

APPLICANT : GARY RUVKUN AND SCOTT OGG  
TITLE : THERAPEUTIC AND DIAGNOSTIC TOOLS FOR  
IMPAIRED GLUCOSE TOLERANCE CONDITIONS



PATENT  
ATTORNEY DOCKET NO: 00786/351004

THERAPEUTIC AND DIAGNOSTIC TOOLS  
FOR IMPAIRED GLUCOSE TOLERANCE CONDITIONS

5                   Statement as to Federally Sponsored Research

This invention was made in part with support from the Federal government through NIH Grant Nos. AG05790 and AG14161. The Government has certain rights in the invention.

Background of the Invention

10               This invention relates to compositions and methods useful for delaying or ameliorating human diseases associated with glucose intolerance.

This application is a continuation-in-part of PCT/US98/10080, filed May 15, 1998, which is a continuation-in-part of U.S.S.N. 08/888,534, filed July 7, 1997, and U.S.S.N. 08/857,076, filed May 15, 1997.

15               Diabetes is a major disease affecting over 16 million individuals in the United States alone at an annual cost of over 92 billion dollars. Type I diabetes or insulin-dependent diabetes (IDDD) is an autoimmune disease. In the IDDM patient, the immune system attacks and destroys the insulin-producing beta cells in the pancreas. The central role of insulin in human metabolism is to aid in the  
20               transport of glucose into muscle cells and fat cells. The body's inability to produce insulin results in hyperglycemia, ketoacidosis, thirst, and weight loss. In addition, diabetics often suffer from chronic atherosclerosis and kidney and eyesight failure. A patient with IDDM requires daily injections of insulin to